A 70-year-old man with metastatic castration-resistant prostate cancer and new bone pain after docetaxel
A 70-year-old man has metastatic castration-resistant prostate cancer with bone metastases and a rising PSA (from 12 to 48 ng/mL over 3 months) despite androgen deprivation therapy with leuprolide. He completed 6 cycles of docetaxel 6 months ago with an initial PSA response, but now has new lower back pain and a PSA of 48 ng/mL. Imaging shows new sclerotic lesions in the lumbar spine and a stable small lung nodule. He has an ECOG performance status of 1 and no visceral disease. Labs: hemoglobin 10.2 g/dL, platelets 180,000/µL, ANC 2,400/µL, creatinine 1.0 mg/dL, alkaline phosphatase 210 U/L, and testosterone <50 ng/dL. He asks about next-line therapy and about bone health.
1. What are the next-line systemic options, and how would you choose among them?
Read the worked answer
Options after docetaxel in mCRPC include:
- Androgen receptor pathway inhibitors (ARPIs): abiraterone plus prednisone or enzalutamide. These are reasonable if not previously used; cross-resistance with docetaxel exists but responses can still occur. Monitor for hypertension, hypokalemia, fluid retention (abiraterone) and seizures (enzalutamide).
- Cabazitaxel: a taxane with survival benefit after docetaxel; consider if he had a good initial response to docetaxel and can tolerate further chemotherapy. Watch for neutropenia and neuropathy.
- Radium-223: approved for mCRPC with symptomatic bone metastases and no visceral metastases; it improves survival and reduces skeletal events. He has bone metastases and no visceral disease, making him a candidate. It requires adequate blood counts and close monitoring.
- PARP inhibitors (olaparib, rucaparib) if a BRCA1/2 or other HRR mutation is present; germline and somatic testing should be done.
- 177Lu-PSMA-617 for PSMA-positive disease after ARPI and taxane; PSMA PET imaging would be needed.
- Sipuleucel-T is for asymptomatic or minimally symptomatic mCRPC and is less appropriate with symptomatic bone pain.
- Choice depends on prior ARPI exposure, symptoms, PSMA status, molecular testing, and patient preference.
2. What bone health measures should be instituted?
Read the worked answer
Bone-modifying therapy and supportive care are indicated:
- Denosumab or zoledronic acid to reduce skeletal-related events in mCRPC with bone metastases. Denosumab may be preferred in renal impairment; zoledronic acid requires dose adjustment for creatinine clearance and monitoring of calcium and magnesium.
- Calcium and vitamin D supplementation, with monitoring for hypocalcemia.
- Dental evaluation before starting bone-modifying therapy to reduce osteonecrosis of the jaw risk.
- Pain management and consideration of palliative radiation for focal painful lesions.
- Fall prevention and physical therapy.
- PSA and imaging surveillance every 2–3 months.
3. How would you counsel him about prognosis and goals of care?
Read the worked answer
Counseling should be honest, individualized, and supportive:
- mCRPC after docetaxel is incurable; median survival is typically in the range of 1–2 years, though individual outcomes vary.
- The goal is to prolong survival, control symptoms, and maintain quality of life.
- Discuss the expected benefits and toxicities of each option, and elicit his priorities (e.g., avoiding hair loss, maintaining independence).
- Early palliative care involvement can improve symptom control and mood.
- Advance care planning and discussion of hospice when appropriate should be introduced gradually.
- Reassure him that multiple effective options remain and that treatment can be sequenced.